With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html
The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:
The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.
To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html
The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:
The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Bots on major social media websites have been hyping GameStop and other "meme stocks," although the extent to which they influenced prices was unclear.
Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings
To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html
The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:
The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.
To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this https://www.rootsanalysis.com/reports/256/request-sample.html
The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:
The Biologics Fill / Finish Services Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/biologics-fill--finish-services-market-2019-2030/256.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 180+ page report, which features 45+ figures and 70+ tables, please visit this Antibody Drug Conjugates Market (5th Edition), 2019-2030.
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
3.2. Key Challenges in Pharmaceutical Marketing
3.2.1. Need for Product Differentiation
3.2.2. Growing Demand for Patient Centric Healthcare
3.2.3. Lack of Standard Performance Metrics
3.2.4. Need for Scientific Communication
3.3. Importance of Digital Marketing
3.4. Popular Digital Marketing Strategies
3.4.1. Social Media Marketing
3.4.2. Content Marketing Strategy
3.4.3. Marketing Automation
3.4.4. Search Engine Optimization and Marketing
3.4.5. Artificial Intelligence based Marketing
3.5. Use of Augmented Reality and Virtual Reality (AR / VR) in
Pharmaceutical Digital Marketing
3.6. Growth Constraints in AR / VR Industry
3.7. Future Perspectives
4.1. Chapter Overview
4.2. Digital Marketing in Pharmaceutical Industry: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by AR / VR based Services Offered
4.2.3. Analysis by Type of Digital Marketing Services Offered
4.2.4. Analysis by Secondary Marketing Services Offered
4.2.5. Analysis by Year of Establishment
4.2.6. Analysis by Company Size
4.2.7. Analysis by Geographical Location
5.1. Chapter Overview
5.2. Methodology and Key Parameters
5.2.1. Competitiveness Analysis: AR / VR based Digital Marketing
Service Providers based in North America
5.2.2. Competitiveness Analysis: AR / VR based Digital Marketing
Service Providers based in Europe
5.2.3. Competitiveness Analysis: AR / VR based Digital Marketing
Service Providers based in Asia-Pacific
6.1. Chapter Overview
6.2. ARworks
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook
6.3. CG Life
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook
6.4. CubeZoo
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook
6.6. INVIVO Communications
6.6.1. Company overview
6.6.2. Recent Developments and Future Outlook
6.7. Mindgrub
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook
6.8. Mirum
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook
6.9. PIXACORE
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook
6.10. Quast Media
6.10.1. Company Overview
6.10.2. Recent Developments and Future Outlook
6.11. Random42
6.11.1. Company Overview
6.11.2. Recent Developments and Future Outlook
6.12. Tipping Point Media
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook
6.13. vStream
6.13.1. Company Overview
6.13.2. Recent Developments and Future Outlook
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Digital Marketing Companies
7.3.1. Most Likely Partners
7.3.2. Likely Partners
7.3.3. Less Likely Partners
7.3.4. Least Likely Partners
PHARMA PLAYERS
8.1. Chapter Overview
8.1.1. Analysis by Year
8.1.2. Analysis by Type of Initiative
8.1.3. Analysis by Type of Application Area
8.1.4. Analysis by Type of Solution
8.1.5. Leading Players: Analysis by Number of Initiatives
8.1.6. Leading Partners: Analysis by Number of Initiatives
9.1. Chapter Overview
9.2. Narola Infotech for Zocular
9.2.1. Narola Infotech
9.2.2. Zocular
9.2.3. Business Needs
9.2.4. Objectives Achieved and Solutions Provided
9.3. Viscira for Actelion
9.3.1. Viscira
9.3.2. Actelion
9.3.3. Business Needs
9.3.4. Objectives Achieved and Solutions Provided
9.4. SoftCover VR for LifeLabs
9.4.1. SoftCover VR
9.4.2. LifeLabs
9.4.3. Business Needs
9.4.4. Objectives Achieved and Solutions Provided
9.5. Virtual Reality Ireland for MISA
9.5.1. Virtual Reality Ireland
9.5.2. MISA
9.5.3. Business Needs
9.5.4. Objectives Achieved and Solutions Provided
9.6. ViitorCloud for vCura
9.6.1. ViitorCloud
9.6.2. vCura
9.6.3. Business Needs
9.6.4. Objectives Achieved and Solutions Provided
9.7. Kwebmaker for Lilavati Hospital
9.7.1. Kwebmaker
9.7.2. Lilavati Hospital
9.7.3. Business Needs
9.7.4. Objectives Achieved and Solutions Provided
9.8. Intermind for My Health Meter
9.8.1. Intermind
9.8.2. My Health Meter
9.8.3. Business Needs
9.8.4. Objectives Achieved and Solutions Provided
9.9. VR Vision for Providence Healthcare
9.9.1. VR Vision
9.9.2. Providence Healthcare
9.9.3. Business Needs
9.9.4. Objectives Achieved and Solutions Provided
9.10. CitrusBits for Zoetis
9.10.1. CitrusBits
9.10.2. Zoetis
9.10.3. Business Needs
9.10.4. Objectives Achieved and Solutions Provided
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall AR / VR based Digital Marketing Opportunity in Healthcare
Industry, 2020-2030
10.4. AR / VR based Digital Marketing Opportunity in Healthcare Industry:
Distribution by Type of Technology, 2020 and 2030
10.5. AR / VR based Digital Marketing Opportunity in Healthcare Industry:
Distribution by Product, 2020 and 2030
10.6. AR / VR based Digital Marketing Opportunity in Healthcare Industry:
Distribution by End-User, 2020 and 2030
10.7. AR / VR based Digital Marketing Opportunity in Healthcare Industry:
Distribution by Key Geographical Regions, 2020 and 2030
10.7.1. AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America, 2020-2030
10.7.1.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Distribution by Type of Technology, 2020 and 2030
10.7.1.1.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Share of AR based Services, 2020-2030
10.7.1.1.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Share of VR based Services, 2020-2030
10.7.1.1.3.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Share of Mixed Reality (MR) based Services, 2020-
2030
10.7.1.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Distribution by Type of Product, 2020 and 2030
10.7.1.2.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Share of Hardware Products, 2020-2030
10.7.1.2.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in North America: Share of Software Products, 2020-2030
10.7.2. AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe, 2020-2030
10.7.2.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Distribution by Type of Technology, 2020 and 2030
10.7.2.1.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Share of AR based Services, 2020-2030
10.7.2.1.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Share of VR based Services, 2020-2030
10.7.2.1.3.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Share of MR based Services, 2020-2030
10.7.2.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Distribution by Type of Product, 2020 and 2030
10.7.2.2.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Share of Hardware Products, 2020-2030
10.7.2.2.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Europe: Share of Software Products, 2020-2030
10.7.3. AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific, 2020-2030
10.7.3.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Distribution by Type of Technology, 2020 and 2030
10.7.3.1.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Share of AR based Services, 2020-2030
10.7.3.1.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Share of VR based Services, 2020-2030
10.7.3.1.3.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Share of MR based Services, 2020-2030
10.7.3.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Distribution by Type of Product, 2020 and 2030
10.7.3.2.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Share of Hardware Products, 2020-2030
10.7.3.2.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Asia-Pacific: Share of Software Products, 2020-2030
10.7.1. AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World, 2020-2030
10.7.1.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Distribution by Type of Technology, 2020 and
2030
10.7.1.1.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Share of AR based Services, 2020-2030
10.7.1.1.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Share of VR based Services, 2020-2030
10.7.1.1.3.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Share of MR based Services, 2020-2030
10.7.1.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Distribution by Type of Product, 2020 and 2030
10.7.1.2.1.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Share of Hardware Products, 2020-2030
10.7.1.2.2.AR / VR based Digital Marketing Opportunity in Healthcare Industry
in Rest of the World: Share of Software Products, 2020-2030
11.1. Chapter Overview
11.2. Unanimity Information & Technology
11.2.1. Interview Transcript: Pritam Sahu, Director, Unanimity Information &
Technology
11.3. Kwebmaker
11.3.1. Interview Transcript: Dhananjay Arora, Founder and CEO,
Kwebmaker
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Reverse engineer the top sellers' strategies with the intelligent suite of Amazon competitor research tools. Monitor the top sellers and your competitors to learn from them, and eventually outsmart them!
Finding the right product to sell on Amazon is always a tough one to crack. Start with the right step to success on Amazon. Make it easy by learning 10 ways on how to do Amazon product research without being stuck with too many products. Become a pro-Amazon Product Finder.
Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
According to Roots Analysis, prefilled syringes market is estimated to be worth over USD 2.5 billion by 2030, growing at a CAGR of 8%...
Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link
The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:
The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
3.2. Cancer Immunotherapy
3.2.1. Cancer Immunotherapy Biomarkers
3.2.2. Identification of a Candidate Biomarker
3.2.3. Need for Novel Cancer Biomarkers
3.3. Tumor Mutation Burden (TMB)
3.3.1. Overview
3.3.2. Variation of TMB across Multiple Indications
3.3.3. Methods for Measurement of TMB
3.3.4. Factors Affecting Measurement of TMB
3.3.5. Initiatives for Assessment of TMB as a Potential Biomarker
3.4. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
3.4.1. Overview
3.4.2. Variation of MSI across Multiple Indications
3.4.3. Methods of Measurement of MSI
3.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers
4 CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cancer Biomarkers Testing Services: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Test Availability
4.2.5. Analysis by Type of Biomarker
4.2.6. Analysis by Application Area
4.2.7. Analysis by Disease Indication
4.2.8. Analysis by Analytical Technique Used
4.2.9. Analysis by Turnaround Time
4.2.10. Analysis by Sample Input
4.2.11. Analysis by Nucleic Acid Tested
4.2.12. Key Players: Analysis by Type of Biomarker
4.3. TMB Tests
4.3.1. Analysis by Application Area
4.3.2. Analysis by Disease Indication
4.3.3. Analysis by Analytical Technique Used
4.3.4. Analysis by Turnaround Time
4.4. MSI / MMR Tests
4.4.1. Analysis by Application Area
4.4.2. Analysis by Disease Indication
4.4.3. Analysis by Analytical Technique Used
4.4.4. Analysis by Turnaround Time
4.5. TIL-based Tests
4.5.1. Analysis by Application Area
4.5.2. Analysis by Disease Indication
4.5.3. Analysis by Analytical Technique Used
4.5.4. Analysis by Turnaround Time
5 PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Tests for the Assessment of TMB
5.2.2. Tests for the Assessment of MSI / MMR
5.2.3. Tests for the Assessment of TILs
6 COMPANY PROFILES
6.1. Chapter Overview
6.2. Dr Lal PathLabs
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Product / Service Portfolio
6.2.3.1. Biomarkers Testing Portfolio
6.2.3.1.1. Microsatellite Instability (MSI) by PCR
6.2.3.1.2. OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI)
6.2.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with MSI
6.2.4. Recent Developments and Future Outlook
6.3. Foundation Medicine
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Product / Service Portfolio
6.3.3.1. Biomarkers Testing Portfolio
6.3.3.1.1. FoundationOne CDx
6.3.3.1.2. FoundationOne Liquid
6.3.3.1.3. FoundationOne Heme
6.3.4. Recent Developments and Future Outlook
6.4. NeoGenomics Laboratories
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Product / Service Portfolio
6.4.3.1. Biomarkers Testing Portfolio
6.4.3.1.1. NeoTYPE Discovery Profile for Solid Tumors
6.4.3.1.2. MSI Analysis / MMR Panel by IHC
6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte Panel
6.4.4. Recent Developments and Future Outlook
6.5. Novogene
6.5.1. Company Overview
6.5.2. Product / Service Portfolio
6.5.2.1. Biomarkers Testing Portfolio
6.5.2.1.1. NovoPM Cancer Panel
6.5.2.1.2. NovoPM TMB
6.5.2.1.3. NovoPM bTMB
6.5.2.1.4. NovoPM MSI
6.5.3. Recent Developments and Future Outlook
6.6. Q2 Solutions
6.6.1. Company Overview
6.6.2. Product / Service Portfolio
6.6.2.1. Biomarkers Testing Portfolio
6.6.2.1.1. TMB Assay
6.6.2.1.2. MSI Assay
6.6.2.1.3. TILs Testing
6.6.3. Recent Developments and Future Outlook
6.7. Personal Genome Diagnostics
6.7.1. Company Overview
6.7.2. Product / Service Portfolio
6.7.2.1. Biomarkers Testing Portfolio
6.7.2.1.1. PGDx elio Tissue Complete Assay
6.7.2.1.2. PlasmaSELECT-R 64
6.7.2.1.3. CancerXOME-R
6.7.2.1.4. CancerSELECT-R 125
6.7.2.1.5. MutatorDETECT
6.7.3. Recent Developments and Future Outlook
6.8. Shenzhen Yuce Biotechnology
6.8.1. Company Overview
6.8.2. Product / Service Portfolio
6.8.2.1. Biomarkers Testing Portfolio
6.8.2.1.1. YuceOne Plus
6.8.2.1.2. YuceOne ICIs
6.8.2.1.3. ct-DNA TMB
6.8.2.1.4. Microsatellite (MSI) Test
6.8.3. Recent Developments and Future Outlook
7 PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Cancer Biomarkers: List of Publications
7.3.1. Analysis by Year of Publication, 2016-2019
7.3.2. Analysis by Year of Publication and Type of Biomarker
7.3.3. Analysis by Year of Publication and Disease Indication
7.3.4. Analysis by Year of Publication and Analytical Technique Used
7.3.5. Analysis by Year of Publication and Type of Cancer Therapy
7.3.6. Most Popular Journals
7.4. Publication Analysis: TMB
7.4.1. Analysis by Year of Publication, 2016-2019
7.4.2. Analysis by Disease Indication
7.4.3. Analysis by Analytical Technique Used
7.4.4. Most Popular Journals
7.5. Publication Analysis: MSI / MMR
7.5.1. Analysis by Year of Publication, 2016-2019
7.5.2. Analysis by Disease Indication
7.5.3. Analysis by Analytical Technique Used
7.5.4. Most Popular Journals
7.6. Publication Analysis: TILs
7.6.1. Analysis by Year of Publication, 2016-2019
7.6.2. Analysis by Disease Indication
7.6.3. Analysis by Analytical Technique Used
7.6.4. Most Popular Journals
8 INNOVATIVE DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS
8.1. Background and Context
8.2. Biomarker-based Clinical Trial Designs
8.2.1. Enrichment Design
8.2.2. All-Comers Design
8.2.3. Mixture / Hybrid Design
8.2.4. Adaptive Design
8.3 Regulatory Considerations
9 CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Cancer Biomarkers: List of Clinical Trials
9.4. Clinical Trial Analysis: TMB
9.4.1. Analysis by Trial Registration Year
9.4.2. Analysis by Trial Recruitment Status
9.4.3. Analysis by Trial Phase
9.4.4. Analysis by Trial Design
9.4.5. Analysis by Disease Indication
9.4.6. Most Active Players
9.4.7. Analysis by Number of Clinical Trials and Geography
9.4.8. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
9.4.9. Analysis by Enrolled Patient Population and Geography
9.4.10. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
9.5. Clinical Trial Analysis: MSI / MMR
9.5.1. Analysis by Trial Registration Year
9.5.2. Analysis by Trial Recruitment Status
9.5.3. Analysis by Trial Phase
9.5.4. Analysis by Trial Design
9.5.5. Analysis by Disease Indication
9.5.6. Most Active Players
9.5.7. Analysis by Number of Clinical Trials and Geography
9.5.8. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
9.5.9. Analysis by Enrolled Patient Population and Geography
9.5.10. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
9.6. Clinical Trial Analysis: TILs
9.6.1. Analysis by Trial Registration Year
9.6.2. Analysis by Trial Recruitment Status
9.6.3. Analysis by Trial Phase
9.6.4. Analysis by Trial Design
9.6.5. Analysis by Disease Indication
9.6.6. Most Active Players
9.6.7. Analysis by Number of Clinical Trials and Geography
9.6.8. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
9.6.9. Analysis by Enrolled Patient Population and Geography
9.6.10. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
9.7 Clinical Trials Summary: Analysis by Registration Year and Biomarker
9.8 Clinical Trials Summary: Analysis by Registration Year and Disease Indication
10.1. Chapter Overview
10.2. Assumptions
10.3 Forecast Methodology
10.4. Global Cancer Biomarkers Testing Market, 2019-2030 (By Value)
10.5. Global Cancer Biomarkers Testing Market, 2019-2030 (By Volume)
10.6. Cancer Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Value)
10.7. Cancer Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Volume)
10.8. Cancer Biomarkers Testing Market: Distribution by Type of Test, 2019-2030 (By Value)
10.8.1. Cancer Biomarkers Testing Market: Distribution by Type of test and Geography, 2019-2030 (By Value)
10.9. Cancer Biomarkers Testing Market: Distribution by Type of test, 2019-2030 (By Volume)
10.9.1. Cancer Biomarkers Testing Market: Distribution by Type of test and Geography, 2019-2030 (By Volume)
10.10. Cancer Biomarkers Testing Market: Distribution by Disease Indication, 2019-2030 (By Value)
10.11. Cancer Biomarkers Testing Market: Distribution by Disease Indication, 2019-2030 (By Volume)
10.12. Cancer Biomarkers Testing Market: Distribution by Analytical Technique, 2019-2030 (By Value)
10.12.1. Cancer Biomarkers Testing Market: Distribution by Analytical Technique and Geography, 2019- 2030 (By Value)
10.13. Cancer Biomarkers Testing Market: Distribution by Analytical Technique, 2019-2030 (By Volume)
10.13.1. Cancer Biomarkers Testing Market: Distribution by Analytical Technique and Geography, 2019-2030 (By Volume)
10.14. Cancer Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Value)
10.15. Cancer Biomarkers Testing Market for TMB, 2019-2030 (By Value)
10.15.1. Cancer Biomarkers Testing Market for TMB: Distribution by Geography, 2019-2030 (By Value)
10.15.2. Cancer Biomarkers Testing Market for TMB: Distribution by Cancer Indication, 2019-2030 (By Value)
10.15.3. Cancer Biomarkers Testing Market for TMB: Distribution by Analytical Technique, 2019-2030 (By Value)
10.15.4. Cancer Biomarkers Testing Market for TMB: Distribution by Type of test, 2019-2030 (By Value)
10.16. Cancer Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Value)
10.16.1. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Geography, 2019-2030 (By Value)
10.16.2. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Cancer Indication, 2019-2030 (By Value)
10.16.3. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Analytical Technique, 2019-2030 (By Value)
10.16.4. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Type of test, 2019-2030 (By Value)
10.17. Cancer Biomarkers Testing Market for TILs, 2019-2030 (By Value)
10.17.1. Cancer Biomarkers Testing Market for TILs: Distribution by Geography, 2019-2030 (By Value)
10.17.2. Cancer Biomarkers Testing Market for TILs: Distribution by Cancer Indication, 2019-2030 (By Value)
10.17.3. Cancer Biomarkers Testing Market for TILs: Distribution by Analytical Technique, 2019-2030 (By Value)
10.17.4. Cancer Biomarkers Testing Market for TILs: Distribution by Type of test, 2019-2030 (By Value)
10.18. Cancer Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Volume)
10.19. Cancer Biomarkers Testing Market for TMB, 2019-2030 (By Volume)
10.19.1. Cancer Biomarkers Testing Market for TMB: Distribution by Geography, 2019-2030 (By Volume)
10.19.2. Cancer Biomarkers Testing Market for TMB: Distribution by Cancer Indication, 2019-2030 (By Volume)
10.19.3. Cancer Biomarkers Testing Market for TMB: Distribution by Analytical Technique, 2019-2030 (By Volume)
10.19.4. Cancer Biomarkers Testing Market for TMB: Distribution by Type of test, 2019-2030 (By Volume)
10.20. Cancer Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Volume)
10.20.1. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Geography, 2019-2030 (By Volume)
10.20.2. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Cancer Indication, 2019-2030 (By Volume)
10.20.3. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Analytical Technique, 2019-2030 (By Volume)
10.20.4. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Type of test, 2019-2030 (By Volume)
10.21. Cancer Biomarkers Testing Market for TILs, 2019-2030 (By Volume)
10.21.1. Cancer Biomarkers Testing Market for TILs: Distribution by Geography, 2019-2030 (By Volume)
10.21.2. Cancer Biomarkers Testing Market for TILs: Distribution by Cancer Indication, 2019-2030 (By Volume)
10.21.3. Cancer Biomarkers Testing Market for TILs: Distribution by Analytical Technique, 2019-2030 (By Value)
10.21.4. Cancer Biomarkers Testing Market for TILs: Distribution by Type of Test, 2019-2030 (By Value)
11.1. Chapter Overview
11.1.1. Increasing Focus on Precision Medicine
11.1.2. Rise in Number of Biomarker-based Clinical Trials
11.1.3. Emerging Technologies for Biomarker Assessment
11.1.4. Development of Companion Diagnostic Products
11.1.5. Other Opportunities
12.1. Chapter Overview
12.2. Companion Diagnostics: Needs of Different Stakeholders
12.3. Comparison of Needs of Various Stakeholders
12.3.1. Needs of Drug Developers
12.3.2. Needs of Companion Diagnostics Developers
12.3.3. Needs of Regulatory Authorities
12.3.4. Needs of Testing Laboratories
12.3.5. Needs of Payers / Insurance Providers
12.3.6. Needs of Physicians
12.3.7. Needs of Patients
13.1. Chapter Overview
13.2. Companion Diagnostics: Components of the Value Chain
13.3. Companion Diagnostics Value Chain: Cost Distribution
13.3.1. Companion Diagnostics Value Chain: Costs Associated with Research and Product Development
13.3.2. Companion Diagnostics Value Chain: Costs Associated with Costs Associated with Manufacturing and Assembly
13.3.3. Companion Diagnostics Value Chain: Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
13.3.4. Companion Diagnostics Value Chain: Costs Associated with Payer Negotiation and KoL Engagement
13.3.5. Companion Diagnostics Value Chain: Costs Associated with Marketing and Sales
14.1. Chapter Overview
14.2. Methodology
14.3. Clinical Trial Analysis
14.3.1. List of Likely Drug Candidates for IVD Developers
14.4. Cumulative Distribution of Biomarker-based Trials by Registration Year, 2016-2019
14.4.1. Analysis of Biomarker-based Trials of Most Popular Biomarkers
14.4.2. Analysis of Biomarker-based Trials of Moderately Popular Biomarkers
14.4.3. Analysis of Biomarker-based Trials of Less Popular / Other Biomarkers
14.4.4. Word Cloud of Other Emerging Biomarkers
14.4.5. Cumulative Distribution of Trials by Registration year and Most Popular Biomarkers
14.4.6. Cumulative Distribution of Trials by Registration year and Moderately Popular Biomarkers
14.4.7. Cumulative Distribution of Trials by Registration year and Less Popular / Other Biomarkers
14.5. Distribution of Biomarker-based Trials by Most Popular Indications
14.5.1. Distribution of Biomarker-based Trials by Moderately Popular Indications
14.5.2. Distribution of Biomarker-based Trials by Less Popular / Other Indications
14.5.3. Word Cloud of Other Emerging Indications in Biomarker-based Clinical Trials
14.5.4. Cumulative Distribution of Trials by Registration year and Most Popular Indication
14.5.5. Cumulative Distribution of Trials by Registration year and Moderately Popular Indications
14.5.6. Cumulative Distribution of Trials by Registration year and Less Popular / Other Indications
14.6. Analysis of Biomarker-based Trials by Phase of Development
14.6.1. Analysis of Biomarker-based Trials by Phase of Development and Most Popular Biomarkers
14.6.2. Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Biomarkers
14.6.3. Analysis of Biomarker-based Trials by Phase of Development and Less Popular and Other Biomarkers
14.6.4. Analysis of Biomarker-based Trials by Phase of Development and Most Popular Indications
14.6.5. Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Indications
14.6.6. Analysis of Biomarker-based Trials by Phase of Development and Less Popular and Other Indications
14.7. Analysis of Biomarker-based Trials by Sponsor
14.7.1. Analysis of Biomarker-based Trials by Sponsor and Most Popular Biomarkers
14.7.2. Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Biomarkers
14.7.3. Analysis of Biomarker-based Trials by Sponsor and Most Popular Indications
14.7.4. Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Indications
14.8. Analysis of Biomarker-based Trials by Recruitment Status
14.9. Analysis of Biomarker-based Trials by Therapy Design
14.10. Analysis of Biomarker-based Trials by Geography
14.10.1. Analysis of Biomarker-based Trials by Trial Phase and Recruitment Status
14.11. Clinical Trials Summary: Analysis by Biomarker and Most Popular Indications
14.12. Clinical Trials Summary: Analysis by Biomarker and Moderately Popular Indications
14.13. Clinical Trials Summary: Analysis by Biomarker and Other Emerging Indications
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
According to Roots Analysis, DNA-encoded libraries platforms and services market is projected to be reach USD 4 billion by 2030, growing at a CAGR of 17%...
According to Roots Analysis, Global Smart Lighting Market is projected to reach USD 80.9 Billion by 2030, growing at an annualized rate of 22.3%…
According to Roots Analysis, Global Colocation Datacenter Market is projected to reach USD 170 billion by 2030, growing at an annualized rate of 13.6%…
To order this detailed 370+ page report, please visit this link
Key Inclusions
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
The report features inputs from eminent industry stakeholders, according to whom this relatively novel class of antibody therapeutics is likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:
To request sample pages, please visit this link
Key Questions Answered
You may also be interested in the following titles:
Global Preventive Vaccines Market, 2020-2030
Endocannabinoid System Targeted Therapeutics Market, 2019-2030
Antibody Contract Manufacturing Market, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link
The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:
The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Table of Contents
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Functions of an Antibody
3.5. Mechanism of Action of an Antibody
3.6. Concept of Monoclonal Antibodies
3.7. Antibody Therapeutics
3.8. Historical Evolution of Antibody Therapeutics
3.9. Types of Advanced Antibody Therapeutics
3.9.1. Fc Engineered and Glycoengineered Antibodies
3.9.2. Antibody Fragments
3.9.3. Fusion Proteins
3.9.4. Intrabodies
3.9.5. Bispecific Antibodies
3.10. Bispecific Antibody Formats
3.10.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
3.10.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
3.10.1.2. Bispecific Single-Domain Antibody Fusion Proteins
3.10.1.3. Diabodies / Diabody Derivatives
3.10.1.4. Fusion Proteins
3.10.1.5. Fusion Proteins Devoid of Fc Regions
3.10.2. Immunoglobulin G (IgG)-based Formats (Fc Dependent Antibody Formats)
3.10.2.1. Quadromas
3.10.2.2. Knobs-Into-Holes
3.10.2.3. Dual Variable Domain Ig
3.10.2.4. IgG-scFv
3.10.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
3.10.2.6. Half Molecule Exchange
3.10.2.7. κλ- Bodies
3.11. Mechanisms of Action of Bispecific Antibodies
3.11.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
3.11.2. Directly Targeting Malignant / Tumor Cells
3.11.3. Retargeting of Toxins
3.11.5. Targeting Tumor Angiogenesis
3.11.6. Other Mechanisms
3.12. Applications of Bispecific Antibodies
4 MARKET OVERVIEW
4.1. Chapter Overview
4.2. Bispecific Antibody Therapeutics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.3. Bispecific Antibody Therapeutics: Clinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Antigen
4.3.3. Analysis by Type of Antibody Format
4.3.4. Analysis by Mechanism of Action
4.3.5. Analysis by Disease Indication
4.3.6. Analysis by Therapeutic Area
4.3.7. Analysis by Broader Disease Segment
4.3.8. Analysis by Route of Administration
4.3.9. Analysis by Mode of Administration
4.3.10. Analysis by Patient Segment
4.4. Bispecific Antibody Therapeutics: Early Stage Pipeline
4.4.1. Analysis by Phase of Development
4.4.2. Analysis by Target Antigen
4.4.4. Analysis by Mechanism of Action
4.4.5. Analysis by Therapeutic Area
4.4.6. Analysis by Broader Disease Segment
4.6. Bispecific Antibody Therapeutics: Combination Therapy Candidates
4.7. Bispecific Antibody Therapeutics: Non-Industry Players
4.8. Emerging Novel Antibody Therapeutic Modalities
5 Bispecific Antibody Therapeutics: Technology Platforms
5.1. Chapter Overview
5.2. Bispecific Antibody Therapeutics: List of Technology Platforms
5.3. Bispecific Antibody Therapeutics: Technology Platform Profiles
5.3.1. Bispecific T-cell Engager (BiTE®) (Amgen)
5.3.1.1. Overview
5.3.1.2. Technology Details
5.3.1.3. Structure of BiTE® Bispecific Antibodies
5.3.1.4. Pipeline of BiTE® Bispecific Antibodies
5.3.1.5. Advantages of BiTE® Bispecific Antibodies
5.3.1.6. Partnerships and Collaborations
5.3.2. DuoBody® (Genmab)
5.3.2.1. Overview
5.3.2.2. Technology Details
5.3.2.3. Structure of DuoBody® Bispecific Antibodies
5.3.2.4. Pipeline of DuoBody® Bispecific Antibodies
5.3.2.5. Advantages of DuoBody® Bispecific Antibodies
5.3.2.6. Partnerships and Collaborations
5.3.3. Xmab™ Antibody Engineering Platform (Xencor)
5.3.3.1. Overview
5.3.3.2. Technology Details
5.3.3.3. Pipeline of Xmab™ Bispecific Antibodies
5.3.3.4. Advantages of Xmab™ Bispecific Antibodies
5.3.3.5. Partnerships and Collaborations
5.3.4. WuXibodyTM Bispecific Engineering Platform (WuXi Biologics)
5.3.4.1. Overview
5.3.4.2. Pipeline of WuXibodyTM Bispecific Antibodies
5.3.4.3. Advantages of WuXibodyTM Bispecific Antibodies
5.3.4.4. Partnerships and Collaborations
5.3.5. Anticalin® (Pieris Pharmaceuticals)
5.3.5.1. Overview
5.3.5.2. Structure of Anticalin® Bispecific Fusion Proteins
5.3.5.3. Pipeline of Anticalin® Bispecific Fusion Proteins
5.3.5.4. Advantages of Anticalin® Bispecific antibody Platform
5.3.5.5. Partnerships and Collaborations
5.3.6. Azymetric™ (Zymeworks)
5.3.6.1. Overview
5.3.6.2. Technology Details
5.3.6.3. Structure of Azymetric™ Bispecific Antibodies
5.3.6.4. Pipeline of Azymetric™ Bispecific Antibodies
5.3.6.5. Advantages of the AzymetricTM Bispecific Antibodies
5.3.6.6. Partnerships and Collaborations
5.4. Geographical Distribution of Technology Providers
5.5. Bispecific Antibody Technology Platforms: Comparative Analysis
6 DRUG PROFILES
6.1. Chapter Overview
6.2. Marketed Drug Profiles
6.2.1. Blincyto™ / Blinatumomab / AMG103 / MT103 (Amgen)
6.2.1.1. Company Overview
6.2.1.1.1. Financial Performance
6.2.1.2. Drug Overview
6.2.1.2.1. Mechanism of Action and Targets
6.2.1.2.2. Dosage
6.2.1.2.3. Current Development Status
6.2.1.2.4. Development Process
6.2.1.2.5. Annual Sales
6.2.2. Hemlibra® / Emicizumab / RG6013 / ACE910 / RO5534262 (Chugai Pharmaceutical / Roche)
6.2.2.1. Company Overview
6.2.2.1.1. Financial Performance
6.2.2.2. Drug Overview
6.2.2.2.1. Mechanism of Action and Targets
6.2.2.2.2. Dosage
6.2.2.2.4. Development Process
6.2.2.2.5. Annual Sales
6.3. Late Stage Drug Profiles
6.4. RG7716 / RO6867461 / Faricimab (Roche / Genentech)
6.4.1 Drug Overview
6.5. Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals)
6.5.1 Drug Overview
6.6. ABT-165 (AbbVie)
6.6.1 Overview of Drug, Current Development Status and Clinical Results
6.7. ABY-035 (Affibody)
6.7.1. Drug Overview
6.8. AFM13 (Affimed)
6.8.1 Drug Overview
6.9. AMG 570 / MEDI0700 (Amgen)
6.9.1. Drug Overview
6.10. KN026 (Alphamab)
6.10.1. Drug Overview
6.11. KN046 (Alphamab)
6.11.1. Drug Overview
6.12. M1095 / ALX-0761 (Merck / Ablynx / Avillion)
6.12.1. Drug Overview
6.13. M7824 / Bintrafusp Alfa (Merck / GlaxoSmithKline)
6.13.1. Drug Overview
6.14. MCLA-128 (Merus)
6.14.1. Drug Overview
6.15. MEDI3902 / Gremubamab (MedImmune /AstraZeneca)
6.15.1. Drug Overview
6.16. Drug Overview
6.17. REGN1979 (Regeneron)
6.17.1. Drug Overview 6.18. ZW25 (Zymeworks)
6.18.1. Drug Overview
7 KEY INSIGHTS
7.1. Chapter Overview
7.2. Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development
7.3. Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action
7.4. Bispecific Antibody Therapeutics: Two-Dimensional Scatter Plot Analysis based on Target Combinations
7.4.1 Key Parameters
7.5. Logo Landscape: Analysis of Developers by Company Size
8 BENCHMARK ANALYSIS: BIG PHARMA PLAYERS
8.1. Chapter Overview
8.2. Top Pharmaceutical Companies
8.2.1. Analysis by Target Antigen
8.2.2. Analysis by Type of Antibody Format
8.2.3. Analysis by Mechanism of Action
8.2.4. Analysis by Therapeutic Area
8.2.5. Analysis by Type of Partnership
9 PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Most Active Developers: Analysis by Number of Partnerships
9.3.5. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
9.3.6. Regional Analysis
9.3.7. Intercontinental and Intracontinental Agreements
10 CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS
10.1. Chapter Overview
10.2. Manufacturing of Bispecific Antibody Therapeutics
10.2.1. Key Manufacturing Considerations and Challenges
10.2.2. Contract Manufacturing Organizations (CMOs)
10.2.2.1. Introduction to CMOs
10.2.2.2. Bispecific Antibody Therapeutics: List of CMOs
10.2.3. Contract Research Organizations (CROs)
10.2.3.1. Introduction to CROs
10.2.3.2. Bispecific Antibody Therapeutics: List of CROs
10.3. Key Considerations for Selecting a Suitable CMO / CRO Partner
11 CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Recruitment Status
11.3.3. Analysis by Trial Phase
11.3.4. Analysis by Trial Design
11.3.5. Analysis by Disease Indication
11.3.6. Analysis by Therapeutic Area
11.3.7. Most Active Players
11.3.8. Analysis by Number of Clinical Trials and Geography
11.3.9. Analysis by Enrolled Patient Population and Geography
12 CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES
12.1. Chapter Overview
12.2. Guidelines Issued by Regulatory Authorities
12.2.1. US Food and Drug Administration (FDA)
12.2.1.1. Pharma Companies Response to the FDA Draft Guidance
12.2.2. World Health Organization (WHO)
12.2.3. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
13 CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES
13.1. Chapter Overview
13.2. Overview of Channels Used for Promotional Campaigns
13.3. Summary: Product Website Analysis
13.4. Summary: Patient Support Services and Informative Downloads
13.5. Promotional Analysis: Blincyto™
13.5.1. Drug Overview
13.5.2. Product Website analysis
13.5.2.1. Messages for Healthcare Professionals
13.5.2.1.1. For MRD Positive B‑cell precursor ALL
13.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL
13.5.2.2. Message for Patients
13.5.3. Patient Support Services and Informative Downloads
13.5.4. Other Promotional Strategies
13.5.4.1. Presence in Conferences
13.6. Promotional Analysis: Hemlibra®
13.6.1. Drug Overview
13.6.2. Product Website Analysis
13.6.2.1. Messages for Healthcare Professionals
13.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
13.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
13.6.2.3. Messages for Patients
13.6.3. Patient Support Services and Informative Downloads
13.6.3.1. Co-pay Program
13.6.3.2. Independent Co-pay Assistance Foundation
13.6.3.3. Genentech Patient Foundation
13.6.4. Other Promotional Strategies
13.6.4.1. Presence in Conferences
14 SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Concluding Remarks
15 MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology and Key Assumptions
15.4. Overall Bispecific Antibody Therapeutics Market, 2019-2030
15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area
15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action
15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Target Antigen
15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Format
15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players
15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Geography
15.5. Bispecific Antibody Market: Value Creation Analysis
15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts
15.6.1. Blincyto
15.6.1.1. Target Patient Population
15.6.1.2. Sales Forecast
15.6.1.3. Net Present Value
15.6.1.4. Value Creation Analysis
15.6.2. Hemlibra
15.6.2.1. Target Patient Population
15.6.2.2. Sales Forecast
15.6.2.3. Net Present Value
15.6.2.4. Value Creation Analysis
15.6.3. RG7716
15.6.3.1. Target patient Population
15.6.3.2. Sales Forecast
15.6.3.3. Net Present Value
15.6.3.4. Value Creation Analysis
15.6.4. Ozoralizumab
15.6.4.1. Target Patient Population
15.6.4.2. Sales Forecast
15.6.4.3. Net Present Value
15.6.4.4. Value Creation Analysis
15.6.5. ABY-035
15.6.5.1. Target Patient Population
15.6.5.2. Sales Forecast
15.6.5.3. Net Present Value
15.6.5.4. Value Creation Analysis
15.6.6. AFM13
15.6.6.1. Target Patient Population
15.6.6.2. Sales Forecast
15.6.6.3. Net Present Value
15.6.6.4. Value Creation Analysis
15.6.7. M1095
15.6.7.1. Target Patient Population
15.6.7.2. Sales Forecast
15.6.7.3. Net Present Value
15.6.7.4. Value Creation Analysis
15.6.8. MEDI3902
15.6.8.1. Target Patient Population
15.6.8.2. Sales Forecast
15.6.8.3. Net Present Value
15.6.8.4. Value Creation Analysis
15.6.9. ABT-981
15.6.9.1. Target Patient Population
15.6.9.2. Sales Forecast
15.6.9.3. Net Present Value
15.6.9.4. Value Creation Analysis
15.6.10. SAR156597
15.6.10.1. Target Patient Population
15.6.10.2. Sales Forecast
15.6.10.3. Net Present Value
15.6.10.4. Value Creation Analysis
16 CONCLUDING REMARKS
17 EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. CytomX Therapeutics
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Siobhan Pomeroy, Senior Director, Business Development (Q3 2017)
17.3. F-star
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Jane Dancer, Chief Business Officer (Q3 2017)
17.4. Innovent Biologics
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Yinjue Wang, Associate Director, Process Development (Q3 2017)
17.5. Synimmune
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Ludger Große-Hovest, Chief Scientific Officer, and Martin Steiner, Chief Executive Officer
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
To order this 350+ page report, please visit this link
Key Inclusions
The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Press Release: Variation 4 (Format 5)
The report also features inputs from eminent industry stakeholders, according to whom liquid biopsy has the potential to diagnose cancer at a very early stage by analyzing rare circulating tumour markers, thereby, facilitating appropriate / timely treatment decisions. The report includes detailed transcripts of discussions held with the following experts:
To request sample pages, please visit this link
Key Questions Answered
Press Release: Variation 4 (Format 5)
You may also be interested in the following titles:
Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.
To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link
The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:
Press Release: Variation 3 (Format 4)
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Cancer Detection
3.4. Cancer Screening and Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
Press Release: Variation 2 (Format 3)
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
3.7.1. Circulating Tumor Cells
3.7.2. Circulating Tumor DNA
3.7.3. Exosomes
3.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.10. Challenges Associated with Non-Invasive Cancer Diagnostics
3.11. Future Perspectives
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)
4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Papanicolaou Test and Human Papilloma Virus Test
4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players
5.2.4. Analysis by Geography
5.3. Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Status of Development
5.3.2. Analysis by Type of Product
5.3.3. Analysis by Application Area
Press Release: Variation 2 (Format 3)
5.3.4. Analysis by Target Cancer Indication
5.3.5. Analysis by Type of Tumor Marker
5.3.6. Analysis by End User
5.3.7. Analysis by Turnaround Time
5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables
5.5. Liquid Biopsy Products: List of Contract Service Providers
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook
To order this detailed 200+ page report, please visit this link
Key Inclusions
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
To request sample pages, please visit this link
Key Questions Answered
You may also be interested in the following titles:
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Human factors engineering and usability testing have now become an essential part of product design across almost all industries, offering developers the chance to optimize proprietary products in alignment to the preferences of consumers
To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link
The USD 1 Billion (by 2030) financial opportunity within the human factors engineering and usability testing market has been analysed across the following segments:
The Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Context and Background
3.2. Overview of Human Factors Engineering and Usability Testing
3.2.1. Human Factors Engineering (HFE)
3.2.2. Usability Testing
3.2.3. Ergonomics and Hedonomics
3.3. Human Factors Considerations for Medical Device Design
3.3.1. Users
3.3.2. Use Environment
3.3.3. Device-User Interface
3.4. Human Factors and Usability Testing Process
3.5. Advantages of Outsourcing HFE Testing Operations
3.6. Risks and Challenges Associated with Outsourcing HFE Testing Services
3.7. Key Considerations for Selecting an HFE and Usability Testing Partner
4.1. Chapter Overview
4.2. Key Regulatory Authorities on Human Factors and Usability Testing Services
4.3. Regulatory Landscape in North America
4.3.1. FDA Recognized Standards on Human Factors
4.3.2. FDA Guidance Documents related to Human Factors
4.3.3. FDA Human Factors Engineering Process
4.4. Regulatory Landscape in Europe
4.4.1. EU-Recognized Standards on Human Factors
4.4.2. EU Human Factors Engineering Process
4.5. Human Factors Engineering Pathway: Comparison of Guidelines in the US and EU
4.5.1. Alignment between Regulations in the US and EU
4.5.2. Abbreviated Human Factors Engineering and Usability Testing
4.6. Concluding Remarks
5.1. Chapter Overview
5.2. Human Factors Engineering and Usability Testing Service Providers for Medical Devices: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Types of Certifications Obtained
5.2.5. Analysis by Types of Medical Device Designed
5.2.6. Analysis by Types of Human Factors Engineering and Usability Testing Services Offered
5.2.6.1. Analysis by Types of Services Offered in the Concept Phase
5.2.6.2. Analysis by Types of Services Offered in the Design and Development Phase
5.2.6.3. Analysis by Types Services Offered in the Verification and Validation Phase
5.2.7. Analysis by Other Services Offered
5.3. Human Factors Engineering and Usability Testing Service Providers for Medical Devices Software: Overall Market Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis
6.4.1. Human Factors Engineering and Usability Testing Service Providers based in North America
6.4.2. Human Factors Engineering and Usability Testing Service Providers based in Europe
6.4.3. Human Factors Engineering and Usability Testing Service Providers based in Asia
Pacific / RoW
7.1. Chapter Overview
7.2. Service Providers in North America
7.2.1. Agilis
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.3. Future Outlook
7.2.2. Human Factors Consulting Service
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.3. Future Outlook
7.2.3. Human Factors MD
7.2.3.1. Company Overview
7.2.3.2. Service Portfolio
7.2.3.3. Future Outlook
7.2.4. User wise
7.2.4.1. Company Overview
7.2.4.2. Service Portfolio
7.2.4.3. Future Outlook
7.2.5. Ximedica
7.2.5.1. Company Overview
7.2.5.2. Service Portfolio
7.2.5.3. Future Outlook
7.3. Service Providers in Europe
7.3.1. Austrian Center for Medical Innovation and Technology (ACMIT)
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.3. Future Outlook
7.3.2. Auxergo
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Future Outlook
7.3.3. THAY Medical
7.3.3.1. Company Overview
7.3.3.2. Service Portfolio
7.3.3.3. Future Outlook
7.4. Service Providers in Asia Pacific
7.4.1. Ergotech
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.3. Future Outlook
7.4.2. Jonathan Bar-Or Industrial Design
7.4.2.1. Company Overview
7.4.2.2. Service Portfolio
7.4.2.3. Future Outlook
8.1. Chapter Overview
8.2. Steps involved in Human Factors Engineering and Usability Testing Process
8.3. Cost Distribution across the Different Steps of Human Factors Engineering and Usability Testing Process
8.3.1. Costs Associated with Contextual Inquiry
8.3.2. Costs Associated with Task Analysis
8.3.3. Costs Associated with Human Factors Assessment for Device Design
8.3.4. Costs Associated with Formative Studies
8.3.5. Costs Associated with Risk Analysis
8.3.6. Costs Associated with Use Error Analysis
8.3.7. Costs Associated with Summative Studies
8.3.8 Costs Associated with Regulatory Document Preparation
To order this 350+ page report, please visit this link
Key Inclusions
The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Press Release: Variation 4 (Format 5)
The report also features inputs from eminent industry stakeholders, according to whom liquid biopsy has the potential to diagnose cancer at a very early stage by analyzing rare circulating tumour markers, thereby, facilitating appropriate / timely treatment decisions. The report includes detailed transcripts of discussions held with the following experts:
To request sample pages, please visit this link
Key Questions Answered
Press Release: Variation 4 (Format 5)
You may also be interested in the following titles:
Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.
To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link
The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:
Press Release: Variation 3 (Format 4)
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Cancer Detection
3.4. Cancer Screening and Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
Press Release: Variation 2 (Format 3)
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
3.7.1. Circulating Tumor Cells
3.7.2. Circulating Tumor DNA
3.7.3. Exosomes
3.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.10. Challenges Associated with Non-Invasive Cancer Diagnostics
3.11. Future Perspectives
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)
4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Papanicolaou Test and Human Papilloma Virus Test
4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players
5.2.4. Analysis by Geography
5.3. Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Status of Development
5.3.2. Analysis by Type of Product
5.3.3. Analysis by Application Area
Press Release: Variation 2 (Format 3)
5.3.4. Analysis by Target Cancer Indication
5.3.5. Analysis by Type of Tumor Marker
5.3.6. Analysis by End User
5.3.7. Analysis by Turnaround Time
5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables
5.5. Liquid Biopsy Products: List of Contract Service Providers
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. DiaCarta
6.3.1. Company Overview
6.3.2. Liquid Biopsy Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. HaploX
6.4.1. Company Overview
6.4.2. Liquid Biopsy Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. NeoGenomics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Liquid Biopsy Product Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. QIAGEN
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Liquid Biopsy Product Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Swift Biosciences
6.7.1. Company Overview
6.7.2. Liquid Biopsy Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Sysmex Inostics
6.8.1. Company Overview
6.8.2. Liquid Biopsy Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Thermo Fisher Scientific
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Liquid Biopsy Product Portfolio
6.9.4. Recent Developments and Future Outlook
7.1. Chapter Overview
Press Release: Variation 2 (Format 3)
7.2. Partnership Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Tumor Marker
7.3.4. Analysis by Target Cancer Indication
7.3.5. Analysis by Type of Partner
7.3.6. Most Active Players: Analysis by Number of Partnerships
7.3.7. Regional Analysis
7.3.7.1. Intercontinental and Intracontinental Agreements
8.1. Chapter Overview
8.2. Types of Funding
8.3. List of Funding and Investment Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Target Cancer Indication
8.3.5. Analysis by Type of Tumor Marker
8.3.6. Most Active Players: Analysis by Amount Invested
8.3.7. Most Active Investors: Analysis by Number of Funding Instances
8.3.8. Regional Analysis by Amount Invested
8.4. Concluding Remarks
9.1. Chapter Overview
9.2. Top Pharmaceutical Companies
9.2.1. Analysis by Status of Development
9.2.2. Analysis by Type of Tumor Marker
9.2.3. Analysis by Application Area
9.2.4. Analysis by Target Cancer Indication
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World
10.7. Concluding Remarks
11.1. Chapter Overview
11.2. Non-Blood-based Biomarker Detection Tests
11.3. FOBT and Fecal Immunochemical Tests (FIT)
11.4. Pigmented Lesion Assays
11.5. Stool DNA (sDNA)-based Tests
11.6. Volatile Organic Compound (VOC) Detection Tests
11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
Press Release: Variation 2 (Format 3)
12.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030
12.3.1. Global Liquid Biopsy Market, 2019-2030
12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030
12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
12.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030
12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
12.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
12.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
12.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
12.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030
12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
12.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
12.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
12.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
12.3.1.5.3. Global Liquid Biopsy Market for Other End Users, 2019-2030
12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
12.3.1.6.1. Liquid Biopsy Market in the US, 2019-2030
12.3.1.6.2. Liquid Biopsy Market in the UK, 2019-2030
12.3.1.6.3. Liquid Biopsy Market in Germany, 2019-2030
12.3.1.6.4. Liquid Biopsy Market in France, 2019-2030
12.3.1.6.5. Liquid Biopsy Market in Italy, 2019-2030
12.3.1.6.6. Liquid Biopsy Market in Spain, 2019-2030
12.3.1.6.7. Liquid Biopsy Market in Japan, 2019-2030
12.3.1.6.8. Liquid Biopsy Market in China, 2019-2030
12.3.1.6.9. Liquid Biopsy Market in India, 2019-2030
12.3.1.6.10. Liquid Biopsy Market in Australia, 2019-2030
12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030
13.1. Chapter Overview
13.2. Company Specifics of Respondents
13.3. Designation of Respondents
13.4. Type of Product Portfolio
13.5. Types of Products / Services Offered
13.6. Application Area
Press Release: Variation 2 (Format 3)
13.7. Status of Development of the Products
13.8. Likely Market Size
14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care
in the Field of Oncology
14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer
Management
14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range
of Applications
14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different
Geographies
14.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further
Strengthen the Ongoing Innovation
14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
14.8. Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged
as a Multi-Billion Dollar Market
15.1. Chapter Overview
15.2. Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer,
Theranosis Life Sciences
15.3. Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical
Operations
15.4. Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer
Diagnostics
15.5. Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics
15.6. Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International
15.7. Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics
15.8. Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech
15.9. Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics
15.10. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect
15.11. Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA
15.12. Interview Transcript: Abizar Lakdawalla, Founder, Proxeom
15.13. Interview Transcript: Mark Li, CEO, Resolution Bioscience
15.14. Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical
15.15. Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA
15.16. Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
To order this detailed 200+ page report, please visit this link
Key Inclusions
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
To request sample pages, please visit this link
Key Questions Answered
You may also be interested in the following titles:
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
Human factors engineering and usability testing have now become an essential part of product design across almost all industries, offering developers the chance to optimize proprietary products in alignment to the preferences of consumers
To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link
The USD 1 Billion (by 2030) financial opportunity within the human factors engineering and usability testing market has been analysed across the following segments:
The Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
According to Roots Analysis, Next-Generation Sequencing Market is projected to be worth USD 19 billion, growing at a CAGR of more than 15% till 2030…
Roots Analysis has done a detailed study on Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Context and Background
3.2. Overview of Human Factors Engineering and Usability Testing
3.2.1. Human Factors Engineering (HFE)
3.2.2. Usability Testing
3.2.3. Ergonomics and Hedonomics
3.3. Human Factors Considerations for Medical Device Design
3.3.1. Users
3.3.2. Use Environment
3.3.3. Device-User Interface
3.4. Human Factors and Usability Testing Process
3.5. Advantages of Outsourcing HFE Testing Operations
3.6. Risks and Challenges Associated with Outsourcing HFE Testing Services
3.7. Key Considerations for Selecting an HFE and Usability Testing Partner
4.1. Chapter Overview
4.2. Key Regulatory Authorities on Human Factors and Usability Testing Services
4.3. Regulatory Landscape in North America
4.3.1. FDA Recognized Standards on Human Factors
4.3.2. FDA Guidance Documents related to Human Factors
4.3.3. FDA Human Factors Engineering Process
4.4. Regulatory Landscape in Europe
4.4.1. EU-Recognized Standards on Human Factors
4.4.2. EU Human Factors Engineering Process
4.5. Human Factors Engineering Pathway: Comparison of Guidelines in the US and EU
4.5.1. Alignment between Regulations in the US and EU
4.5.2. Abbreviated Human Factors Engineering and Usability Testing
4.6. Concluding Remarks
5.1. Chapter Overview
5.2. Human Factors Engineering and Usability Testing Service Providers for Medical Devices: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Types of Certifications Obtained
5.2.5. Analysis by Types of Medical Device Designed
5.2.6. Analysis by Types of Human Factors Engineering and Usability Testing Services Offered
5.2.6.1. Analysis by Types of Services Offered in the Concept Phase
5.2.6.2. Analysis by Types of Services Offered in the Design and Development Phase
5.2.6.3. Analysis by Types Services Offered in the Verification and Validation Phase
5.2.7. Analysis by Other Services Offered
5.3. Human Factors Engineering and Usability Testing Service Providers for Medical Devices Software: Overall Market Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis
6.4.1. Human Factors Engineering and Usability Testing Service Providers based in North America
6.4.2. Human Factors Engineering and Usability Testing Service Providers based in Europe
6.4.3. Human Factors Engineering and Usability Testing Service Providers based in Asia
Pacific / RoW
7.1. Chapter Overview
7.2. Service Providers in North America
7.2.1. Agilis
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.3. Future Outlook
7.2.2. Human Factors Consulting Service
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.3. Future Outlook
7.2.3. Human Factors MD
7.2.3.1. Company Overview
7.2.3.2. Service Portfolio
7.2.3.3. Future Outlook
7.2.4. User wise
7.2.4.1. Company Overview
7.2.4.2. Service Portfolio
7.2.4.3. Future Outlook
7.2.5. Ximedica
7.2.5.1. Company Overview
7.2.5.2. Service Portfolio
7.2.5.3. Future Outlook
7.3. Service Providers in Europe
7.3.1. Austrian Center for Medical Innovation and Technology (ACMIT)
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.3. Future Outlook
7.3.2. Auxergo
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Future Outlook
7.3.3. THAY Medical
7.3.3.1. Company Overview
7.3.3.2. Service Portfolio
7.3.3.3. Future Outlook
7.4. Service Providers in Asia Pacific
7.4.1. Ergotech
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.3. Future Outlook
7.4.2. Jonathan Bar-Or Industrial Design
7.4.2.1. Company Overview
7.4.2.2. Service Portfolio
7.4.2.3. Future Outlook
8.1. Chapter Overview
8.2. Steps involved in Human Factors Engineering and Usability Testing Process
8.3. Cost Distribution across the Different Steps of Human Factors Engineering and Usability Testing Process
8.3.1. Costs Associated with Contextual Inquiry
8.3.2. Costs Associated with Task Analysis
8.3.3. Costs Associated with Human Factors Assessment for Device Design
8.3.4. Costs Associated with Formative Studies
8.3.5. Costs Associated with Risk Analysis
8.3.6. Costs Associated with Use Error Analysis
8.3.7. Costs Associated with Summative Studies
8.3.8 Costs Associated with Regulatory Document Preparation
9.1. Chapter Overview
9.2. Medical Device Recalls
9.3. Five Major Medical Device Recalls Till-date
9.3.1. West Pharmaceutical’s Fluid Transfer Systems
9.3.2. Magellan Diagnostics’ Blood Lead Testing Systems
9.3.3. Cook Medical’s Catheters
9.3.4. Abbott’s Cardiac Pacemakers
9.3.5. CareFusion’s Alaris Pump Module
9.4. Human Factors Engineering: Managing the Risk of Device Recalls
9.4.1. Cost Saving Potential Associated with Human Factors Engineering and Usability Testing
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Overall Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030
10.4. Human Factors Engineering and Usability Testing Services Market: Distribution by Type of Tools Used, 2020, 2025 and 2030
10.4.1. Human Factors Engineering and Usability Testing Services Market for Generative Tools, 2020-2030
10.4.2. Human Factors Engineering and Usability Testing Services Market for Evaluative Tools, 2020-2030
10.5. Human Factors Engineering and Usability Testing Services Market: Distribution by Types of Steps Involved in Usability Testing, 2020, 2025 and 2030
10.5.1. Human Factors Engineering and Usability Testing Services Market for Contextual Analysis, 2020-2030
10.5.2. Human Factors Engineering and Usability Testing Services Market for Task Analysis, 2020-2030
10.5.3. Human Factors Engineering and Usability Testing Services Market for Design Analysis, 2020-2030
10.5.4. Human Factors Engineering and Usability Testing Services Market for Formative Studies, 2020-2030
10.5.5. Human Factors Engineering and Usability Testing Services Market for Use Risk Analysis, 2020-2030
10.5.6. Human Factors Engineering and Usability Testing Services Market for Known Use Error Analysis, 2020-2030
10.5.7. Human Factors Engineering and Usability Testing Services Market for Summative Studies, 2020-2030
10.5.8. Human Factors Engineering and Usability Testing Services Market for Regulatory Document Preparation, 2020-2030
10.6. Human Factors Engineering and Usability Testing Services Market: Distribution by Device Class, 2020,2025 and 2030
10.6.1. Human Factors Engineering and Usability Testing Services Market for Class I Devices, 2020-2030
10.6.2. Human Factors Engineering and Usability Testing Services Market for Class II Devices, 2020-2030
10.6.3. Human Factors Engineering and Usability Testing Services Market for Class III Devices, 2020-2030
10.7. Human Factors Engineering and Usability Testing Services Market: Distribution by Geography, 2020,2025 and 2030
10.7.1. Human Factors Engineering and Usability Testing Services Market in North America, 2020-2030
10.7.1.1. Human Factors Engineering and Usability Testing Services Market in North America: Distribution by Types of Tools, 2020-2030
10.7.1.1.1. Human Factors Engineering and Usability Testing Services Market for Generative Tools in North America, 2020-2030
10.7.1.1.2. Human Factors Engineering and Usability Testing Services Market for Evaluative Tools in North America, 2020-2030
10.7.1.2. Human Factors Engineering and Usability Testing Services Market in North America: Distribution by Types of Steps Involved in Usability Testing, 2020-2030
10.7.1.2.1. Human Factors Engineering and Usability Testing Services for Contextual Analysis in North America, 2020-2030
10.7.1.2.2. Human Factors Engineering and Usability Testing Services Market for Task Analysis in North America, 2020-2030
10.7.1.2.3. Human Factors Engineering and Usability Testing Services Market for Design Analysis in North America, 2020-2030
10.7.1.2.4. Human Factors Engineering and Usability Testing Services Market for Formative Studies in North America, 2020-2030
10.7.1.2.5. Human Factors Engineering and Usability Testing Services Market for Use Risk Analysis in North America, 2020-2030
10.7.1.2.6. Human Factors Engineering and Usability Testing Services Market for Known Use Error Analysis in North America, 2020-2030
10.7.1.2.7. Human Factors Engineering and Usability Testing Services Market for Summative Studies in North America, 2020-2030
10.7.1.2.8. Human Factors Engineering and Usability Testing Services Market for Regulatory Document Preparation in North America, 2020-2030
10.7.1.3. Human Factors Engineering and Usability Testing Services Market in North America: Distribution by Distribution by Device Class, 2020-2030
10.7.1.3.1. Human Factors Engineering and Usability Testing Services Market for Class I Devices in North America, 2020-2030
10.7.1.3.2. Human Factors Engineering and Usability Testing Services Market for Class II Devices in North America, 2020-2030
10.7.1.3.3. Human Factors Engineering and Usability Testing Services Market for Class III Devices in North America, 2020-2030
10.7.2. Human Factors Engineering and Usability Testing Services Market in Europe, 2020-2030
10.7.2.1. Human Factors Engineering and Usability Testing Services Market in Europe: Distribution by Types of Tools, 2020-2030
10.7.2.1.1. Human Factors Engineering and Usability Testing Services Market for Generative Tools in Europe, 2020-2030
10.7.2.1.2. Human Factors Engineering and Usability Testing Services Market for Evaluative Tools in Europe, 2020-2030
10.7.2.2. Human Factors Engineering and Usability Testing Services Market in Europe: Distribution by Types of Steps Involved in Usability Testing, 2020-2030
10.7.2.2.1. Human Factors Engineering and Usability Testing Services for Contextual Analysis in Europe, 2020-2030
10.7.2.2.2. Human Factors Engineering and Usability Testing Services Market for Task Analysis in Europe, 2020-2030
10.7.2.2.3. Human Factors Engineering and Usability Testing Services Market for Design Analysis in Europe, 2020-2030
10.7.2.2.4. Human Factors Engineering and Usability Testing Services Market for Formative Studies in Europe, 2020-2030
10.7.2.2.5. Human Factors Engineering and Usability Testing Services Market for Use Risk Analysis in Europe, 2020-2030
10.7.2.2.6. Human Factors Engineering and Usability Testing Services Market for Known Use Error Analysis in Europe, 2020-2030
10.7.2.2.7. Human Factors Engineering and Usability Testing Services Market for Summative Studies in Europe, 2020-2030
10.7.2.2.8. Human Factors Engineering and Usability Testing Services Market for Regulatory Document Preparation in Europe, 2020-2030
10.7.2.3. Human Factors Engineering and Usability Testing Services Market in Europe: Distribution by Distribution by Device Class, 2020-2030
10.7.2.3.1. Human Factors Engineering and Usability Testing Services Market for Class I Devices in Europe, 2020-2030
10.7.2.3.2. Human Factors Engineering and Usability Testing Services Market for Class II Devices in Europe, 2020-2030
10.7.2.3.3. Human Factors Engineering and Usability Testing Services Market for Class III Devices in Europe, 2020-2030
10.7.3. Human Factors Engineering and Usability Testing Services Market in Asia Pacific, 2020-2030
10.7.3.1. Human Factors Engineering and Usability Testing Services Market in Asia Pacific: Distribution by Types of Tools, 2020-2030
10.7.3.1.1. Human Factors Engineering and Usability Testing Services Market for Generative Tools in Asia Pacific, 2020-2030
10.7.3.1.2. Human Factors Engineering and Usability Testing Services Market for Evaluative Tools in Asia Pacific, 2020-2030
10.7.3.2. Human Factors Engineering and Usability Testing Services Market in Asia Pacific: Distribution by Types of Steps Involved in Usability Testing, 2020-2030
10.7.3.2.1. Human Factors Engineering and Usability Testing Services for Contextual Analysis in Asia Pacific, 2020-2030
10.7.3.2.2. Human Factors Engineering and Usability Testing Services Market for Task Analysis in Asia Pacific, 2020-2030
10.7.3.2.3. Human Factors Engineering and Usability Testing Services Market for Design Analysis in Asia Pacific, 2020-2030
10.7.3.2.4. Human Factors Engineering and Usability Testing Services Market for Formative Studies in Asia Pacific, 2020-2030
10.7.3.2.5. Human Factors Engineering and Usability Testing Services Market for Use Risk Analysis in Asia Pacific, 2020-2030
10.7.3.2.6. Human Factors Engineering and Usability Testing Services Market for Known Use Error Analysis in Asia Pacific, 2020-2030
10.7.3.2.7. Human Factors Engineering and Usability Testing Services Market for Summative Studies in Asia Pacific, 2020-2030
10.7.3.2.8. Human Factors Engineering and Usability Testing Services Market for Regulatory Document Preparation in Asia Pacific, 2020-2030
10.7.3.3. Human Factors Engineering and Usability Testing Services Market in Asia Pacific: Distribution by Distribution by Device Class, 2020-2030
10.7.3.3.1. Human Factors Engineering and Usability Testing Services Market for Class I Devices in Asia Pacific, 2020-2030
10.7.3.3.2. Human Factors Engineering and Usability Testing Services Market for Class II Devices in Asia Pacific, 2020-2030
10.7.3.3.3. Human Factors Engineering and Usability Testing Services Market for Class III Devices in Asia Pacific, 2020-2030
10.7.4. Human Factors Engineering and Usability Testing Services Market in Rest of the World, 2020-2030
11.1. Chapter Overview
11.2. Impact of the COVID-19 Pandemic on the Approval of Medical Devices
11.2.1 The US Scenario
11.2.2. The European Scenario
11.3. Impact of COVID-19 Outbreak of Human Factors Engineering and Usability Testing Process
11.4. Impact of Future Market Opportunity for Human Factors Engineering and Usability Testing Market
11.5. Recuperative Strategies for CMO Business
11.5.1. Strategies for Implementation in the Short / Mid Term
11.5.2. Strategies for Implementation in the Long Term
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Concluding Remarks
13.1. Chapter Overview
13.2. Key Takeaways
14 EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. DCA Design International
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Daniel Jenkins, Head of Research (Human Factors and Interaction)
14.3. THAY Medical
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Greg Thay, Managing Director (THAY Medical)
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
According to Roots Analysis, With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030…
Contract Regulatory Affairs-Management Services Market for medical devices is estimated to be worth USD 820 million by 2030, growing at a CAGR of 6.9%...
According to Report, Companion Diagnostics Services Market is estimated to reach USD 800+ Million by 2030, Growing at an annualized rate of nearly 10%...
To order this detailed 250+ page report, please visit this link
Key Inclusions
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
To request sample pages, please visit this link
Key Questions Answered
You may also be interested in the following titles:
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.
To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link
The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:
The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Table of Contents
3.3. Manufacturing of Biopharmaceuticals
3.3.1. Types of Expression Systems Used
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.1.6. Fungal Expression Systems
3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.2.2. Downstream Processing
3.4. Overview of Contract Manufacturing
3.4.1. Contract Manufacturing Scenario in China
3.5. Need for Outsourcing in the Biopharmaceutical Industry
3.5.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.7. Basic Guidelines for Selecting a CMO Partner
3.8. Advantages of Outsourcing Manufacturing Services
3.8.1. Benefits of Engaging Chinese Contract Service Providers
3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associated with Engaging Chinese Contract Service Providers
3.10. Future Perspective
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-Related Challenges
5.1. Chapter Overview
5.2. Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Type of Product
5.2.7. Analysis by Types of Services Offered
5.2.8. Analysis by Type of Biologic
5.2.9. Analysis by Expression System Used
5.2.10. Analysis by Type of Bioreactor Used
5.2.11. Analysis by Mode of Operation of Bioreactor
5.2.12. Analysis by Packaging Form Used
5.2.13. Analysis by Regulatory Accreditations / Certifications
6.1 Chapter Overview
6.2 ChemPartner Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Recent Developments and Future Outlook
6.3. JHL Biotech
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Recent Developments and Future Outlook
6.4. JOINN Biologics
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Recent Developments and Future Outlook
6.5 MabPlex
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Recent Developments and Future Outlook
6.6. Mycenax Biotech
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Recent Developments and Future Outlook
6.7. WuXi AppTec
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.4. Manufacturing Facilities and Capabilities
6.7.5. Recent Developments and Future Outlook
7.1 Chapter Overview
7.2. Partnership Models
7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.9. Geographical Distribution by Number of Partnerships
7.3.10. Intercontinental and Intracontinental Agreements
8.1. Chapter Overview
8.2. Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link
The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:
The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Table of Contents
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
3.2. Cancer Immunotherapy
3.2.1. Cancer Immunotherapy Biomarkers
3.2.2. Identification of a Candidate Biomarker
3.2.3. Need for Novel Cancer Biomarkers
3.3. Tumor Mutation Burden (TMB)
3.3.1. Overview
3.3.2. Variation of TMB across Multiple Indications
3.3.3. Methods for Measurement of TMB
3.3.4. Factors Affecting Measurement of TMB
3.3.5. Initiatives for Assessment of TMB as a Potential Biomarker
3.4. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
3.4.1. Overview
3.4.2. Variation of MSI across Multiple Indications
3.4.3. Methods of Measurement of MSI
3.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers
4 CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cancer Biomarkers Testing Services: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Test Availability
4.2.5. Analysis by Type of Biomarker
4.2.6. Analysis by Application Area
4.2.7. Analysis by Disease Indication
4.2.8. Analysis by Analytical Technique Used
4.2.9. Analysis by Turnaround Time
4.2.10. Analysis by Sample Input
4.2.11. Analysis by Nucleic Acid Tested
4.2.12. Key Players: Analysis by Type of Biomarker
4.3. TMB Tests
4.3.1. Analysis by Application Area
4.3.2. Analysis by Disease Indication
4.3.3. Analysis by Analytical Technique Used
4.3.4. Analysis by Turnaround Time
4.4. MSI / MMR Tests
4.4.1. Analysis by Application Area
4.4.2. Analysis by Disease Indication
4.4.3. Analysis by Analytical Technique Used
4.4.4. Analysis by Turnaround Time
4.5. TIL-based Tests
4.5.1. Analysis by Application Area
4.5.2. Analysis by Disease Indication
4.5.3. Analysis by Analytical Technique Used
4.5.4. Analysis by Turnaround Time
5 PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Tests for the Assessment of TMB
5.2.2. Tests for the Assessment of MSI / MMR
5.2.3. Tests for the Assessment of TILs
6 COMPANY PROFILES
6.1. Chapter Overview
6.2. Dr Lal PathLabs
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Product / Service Portfolio
6.2.3.1. Biomarkers Testing Portfolio
6.2.3.1.1. Microsatellite Instability (MSI) by PCR
6.2.3.1.2. OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI)
6.2.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with MSI
6.2.4. Recent Developments and Future Outlook
6.3. Foundation Medicine
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Product / Service Portfolio
6.3.3.1. Biomarkers Testing Portfolio
6.3.3.1.1. FoundationOne CDx
6.3.3.1.2. FoundationOne Liquid
6.3.3.1.3. FoundationOne Heme
6.3.4. Recent Developments and Future Outlook
6.4. NeoGenomics Laboratories
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Product / Service Portfolio
6.4.3.1. Biomarkers Testing Portfolio
6.4.3.1.1. NeoTYPE Discovery Profile for Solid Tumors
6.4.3.1.2. MSI Analysis / MMR Panel by IHC
6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte Panel
6.4.4. Recent Developments and Future Outlook
6.5. Novogene
6.5.1. Company Overview
6.5.2. Product / Service Portfolio
6.5.2.1. Biomarkers Testing Portfolio
6.5.2.1.1. NovoPM Cancer Panel
6.5.2.1.2. NovoPM TMB
6.5.2.1.3. NovoPM bTMB
6.5.2.1.4. NovoPM MSI
6.5.3. Recent Developments and Future Outlook
6.6. Q2 Solutions
6.6.1. Company Overview
6.6.2. Product / Service Portfolio
6.6.2.1. Biomarkers Testing Portfolio
6.6.2.1.1. TMB Assay
6.6.2.1.2. MSI Assay
6.6.2.1.3. TILs Testing
6.6.3. Recent Developments and Future Outlook
To order this detailed 250+ page report, please visit this link
Key Inclusions
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
To request sample pages, please visit this link
Key Questions Answered
You may also be interested in the following titles:
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.
To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link
The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:
The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
Table of Contents
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Table of Contents
3.3. Manufacturing of Biopharmaceuticals
3.3.1. Types of Expression Systems Used
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.1.6. Fungal Expression Systems
3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.2.2. Downstream Processing
3.4. Overview of Contract Manufacturing
3.4.1. Contract Manufacturing Scenario in China
3.5. Need for Outsourcing in the Biopharmaceutical Industry
3.5.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.7. Basic Guidelines for Selecting a CMO Partner
3.8. Advantages of Outsourcing Manufacturing Services
3.8.1. Benefits of Engaging Chinese Contract Service Providers
3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associated with Engaging Chinese Contract Service Providers
3.10. Future Perspective
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-Related Challenges
5.1. Chapter Overview
5.2. Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Type of Product
5.2.7. Analysis by Types of Services Offered
5.2.8. Analysis by Type of Biologic
5.2.9. Analysis by Expression System Used
5.2.10. Analysis by Type of Bioreactor Used
5.2.11. Analysis by Mode of Operation of Bioreactor
5.2.12. Analysis by Packaging Form Used
5.2.13. Analysis by Regulatory Accreditations / Certifications
6.1 Chapter Overview
6.2 ChemPartner Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Recent Developments and Future Outlook
6.3. JHL Biotech
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Recent Developments and Future Outlook
6.4. JOINN Biologics
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Recent Developments and Future Outlook
6.5 MabPlex
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Recent Developments and Future Outlook
6.6. Mycenax Biotech
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Recent Developments and Future Outlook
6.7. WuXi AppTec
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.4. Manufacturing Facilities and Capabilities
6.7.5. Recent Developments and Future Outlook
7.1 Chapter Overview
7.2. Partnership Models
7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.9. Geographical Distribution by Number of Partnerships
7.3.10. Intercontinental and Intracontinental Agreements
8.1. Chapter Overview
8.2. Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.2.5. Analysis by Location of Expansion Project
8.2.6. Analysis by Capacity of Expanded Facility
8.2.7. Most Active Players: Analysis by Number of Expansions
8.2.8. Analysis by Region
9.1. Chapter Overview
9.2. Scope and Methodology
9.3 Clinical Trial Analysis: Biologic Drugs
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Trial Status
9.3.4. Geographical Analysis by Number of Clinical Trials
9.3.5. Geographical Analysis by Enrolled Patient Population
9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis of Enrolled Patient Population by Trial Phase
9.3.8. Analysis by Type of Sponsor / Collaborator
9.3.9. Most Active Players: Analysis by Number of Registered Trials
9.3.10. Analysis by Clinical Trial Center
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Overall Landscape of Chinese Biopharmaceutical Contract Manufacturers
10.4. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China
10.5. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
10.6. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
10.7. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Chinese Biopharmaceutical Contract Manufactures: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Expression System Used
11.3.4. Analysis by Location of Manufacturing Facility
11.3.5. Analysis by Company Size and Location of Manufacturing Facility
11.3.6. Analysis by Company Size and Location of Manufacturing Facility
11.4. Concluding Remarks
12.1. Chapter Overview
12.2. List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Company and Year of Initiative
12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Type of Biologic
12.3. Competitive Benchmarking of Big Pharmaceutical Players
12.3.1. Harvey Ball Analysis: Big Pharma Investment Summary
12.3.2. Geographical Analysis by Investment Made
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Chines Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.4. Conclusion
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030
14.3.1. Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030
14.3.2. Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030
14.4. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Expression System Used
14.4.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems
14.4.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Microbial Systems
14.4.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Expression Systems
14.5. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Scale of Operation
14.5.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Preclinical / Clinical Scale Operations
14.5.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Commercial Operations
14.6. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Size of Manufacturers
14.6.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Small Companies
14.6.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies
14.6.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Large and Very Large Companies
14.7. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Type of Biologic
14.7.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Antibodies
14.7.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Vaccines
14.7.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Biologics
15.1. Chapter Overview
15.2. Evaluation of Impact of COVID-19 Outbreak
15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. WuXi AppTec
15.2.1.2. Boehringer Ingelheim
15.2.1.3. GE Healthcare
15.2.1.4. Lonza
15.2.1.5. AmbioPharm
15.2.2. Impact of China Biopharmaceutical Contract Manufacturing Market
15.3. Key Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate Steps
15.3.2. Short / Long-Term Steps
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
16.7. Concluding Remarks
17.1. Chapter Overview
17.2. Outsourcing Activities Anticipated to Increase in Future
17.3. Shift from One-time Contracts to Strategic Partnerships
17.4. Adoption of Innovative Technologies
17.4.1. Single Use Bioreactors
17.4.2. Novel Bioprocessing Techniques
17.4.3. Bioprocess Automation
17.5. Growing Popularity of the Quality by Design Principle in Bioprocessing
17.6. Increasing Focus on Niche Therapeutic Areas
17.7. Biosimilars Market to Contribute to Contract Service Revenues
17.8. Capability and Facility Expansions to Establish One Stop Shop Expertise
17.9. Increase in Financial In-flow and Outsourcing Budgets
17.10. Challenges Faced by Sponsors and Service Providers
17.10.1. Concerns Associated with Single Use Systems
17.10.2. Issues Related to Capacity Fluctuations
17.11. Concluding Remarks
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
According to Report, In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%...
The Prefilled syringe fill / finish services market is estimated to reach close to USD 3 Billion by 2030, Growing at an annualized rate of over 10%...
The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of....
The next generation immune checkpoint inhibitors and stimulators market is projected to be worth USD 12.5 billion, growing at a CAGR of 15%...
